Alkem Laboratories surges on entering into asset purchase agreement with AbbVie

31 Dec 2019 Evaluate

Alkem Laboratories is currently trading at Rs. 2022.20, up by 32.70 points or 1.64% from its previous closing of Rs. 1989.50 on the BSE.

The scrip opened at Rs. 1999.00 and has touched a high and low of Rs. 2034.05 and Rs. 1999.00 respectively. So far 700 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 2149.00 on 19-Nov-2019 and a 52 week low of Rs. 1660.35 on 28-Jun-2019.

Last one week high and low of the scrip stood at Rs. 2048.50 and Rs. 1957.30 respectively. The current market cap of the company is Rs. 24301.59 crore.

The promoters holding in the company stood at 66.04%, while Institutions and Non-Institutions held 14.10% and 19.87% respectively.

Alkem Laboratories has entered into an asset purchase agreement with AbbVie Inc., USA for acquisition of certain assets related to the active pharmaceutical ingredient, Dronabinol which include domain names and trademarks related to ‘Marinol’, New Drug Application registration with USFDA for Marinol, logos, patents designs, know how, technical and manufacturing instructions, inventory manufacturing equipment and such items. The company shall own the NDA and associated assets and will use these to commercially exploit both Branded and Generic sales in US.

Alkem Laboratories is a leading Indian pharmaceutical company with global operations, engaged in the development, manufacture and sale of pharmaceutical and nutraceutical products. The company produces branded generics, generic drugs, active pharmaceutical Ingredients (APIs) and nutraceuticals, which it markets in India and International markets.

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×